Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Evaluation of the Individual Components of the International Metabolic Prognostic Index (IMPI) in the Context of CAR T-Cell Treatment of Lymphoma

Michael Winkelmann, Kai Rejeski, Viktoria Blumenberg, Gabriel Sheikh, Veit L. Buecklein, Matthias Brendel, Michael Von Bergwelt, Marion Subklewe, Wolfgang G Kunz

Blood (2024) 144 (Supplement 1): 7508.

https://doi.org/10.1182/blood-2024-207418

Published: 2024

Journal Articles

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Blood (2024) 144 (Supplement 1): 961.

https://doi.org/10.1182/blood-2024-199060

Published: 2024

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 2883.1.

https://doi.org/10.1182/blood-2024-201478

Published: 2024

Journal Articles

Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Veit L. Buecklein, Francis A. Ayuk, Tobias A.W. Holderried, Christine Mai, Bradley Kievit, Rob Blisset, Brett Doble, Geoff Reid, Laura Reimeir, Caroline Bruns, Sachin Vadgama

Blood (2024) 144 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2024-205589

Published: 2024

Journal Articles

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Viktoria Blumenberg, Maryam Kazerani, Tobias Straub, Francesco Corrado, Vadim Borisov, Stephan Baumann, Galina Busch, Jan Wulf, Agnese Petrera, Kai Rejeski, Christian Schmidt, Benjamin Tast, Michael von Bergwelt-Baildon, Christoph Stein-Thöringer, Veit L. Buecklein, Marion Subklewe

Blood (2024) 144 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2024-208938

Published: 2024

Journal Articles

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Blood (2024) 144 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2024-211459

Published: 2024

Journal Articles

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 3818.

https://doi.org/10.1182/blood-2024-211227

Published: 2024

Journal Articles

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Nora Philipp, Anetta Marcinek, Gerulf Hänel, Daniel Nixdorf, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2023-179286

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Francesco Corrado, Jan Wulf, Tobias Straub, Daniel Nixdorf, Anetta Marcinek, Nora Philipp, Chang-Feng Chu, Christina Zielinski, Michael von Bergwelt-Baildon, Viktoria Blumenberg, Maryam Kazerani, Marion Subklewe, Veit L. Buecklein

Blood (2023) 142 (Supplement 1): 600.

https://doi.org/10.1182/blood-2023-188970

Published: 2023

Journal Articles

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Lis Winter, Lea Pawlowsky, Anetta Marcinek, Bettina Brauchle, Amelie Muth, Maryam Kazerani, Agnese Petrera, Roman Kischel, Alica Joana Emhardt, Maja Rothenberg-Thurley, Annika Maria Dufour, Karsten Spiekermann, Michael Andreeff, Naval Daver, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2023-173826

Published: 2023

Journal Articles

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

Yingshuai Wang, Wenjie Lu, Lisa Rohrbacher, Heinrich Flaswinkel, Alica Joana Emhardt, Giulia Magno, Sascha Haubner, Sebastian Kobold, Heinrich Leonhardt, Karl-Peter Hopfner, Dirk H Busch, Veit L. Buecklein, Daniel Nixdorf, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2023-180890

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler, Bettina Brauchle, Florian Märkl, Nora Philipp, Gerulf Hänel, Anetta Marcinek, Maryam Kazerani, Alica Joana Emhardt, Giulia Magno, Rebecca L. Goldstein, Tobias Straub, Sebastian Kobold, Tara L. Chapman-Arvedson, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3444.

https://doi.org/10.1182/blood-2023-177922

Published: 2023

Journal Articles

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Amelie Muth, Nora Philipp, Anetta Marcinek, Tobias Straub, Lis Winter, Gerulf Hänel, Daniel Nixdorf, Lisa Rohrbacher, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2023-174258

Published: 2023

Journal Articles

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

David M. Cordas dos Santos, Amar Hadzic, Martin E. Kirmaier, Werner Schmitz, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael von Bergwelt-Baildon, Marion Subklewe, Sebastian Theurich

Blood (2023) 142 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2023-186178

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Viktoria Blumenberg, Maryam Kazerani, Stephan Baumann, Tobias Straub, Francesco Corrado, Jan Wulf, Galina Busch, Kai Rejeski, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2023-187495

Published: 2023

NARROW

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Evaluation of the Individual Components of the International Metabolic Prognostic Index (IMPI) in the Context of CAR T-Cell Treatment of Lymphoma

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only